Literature DB >> 25752877

Duchenne muscular dystrophy.

Eppie M Yiu1,2,3,4, Andrew J Kornberg1,3,4.   

Abstract

Duchenne muscular dystrophy, an X-linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness. Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s. The use of corticosteroids, non-invasive respiratory support, and active surveillance and management of associated complications have improved ambulation, function, quality of life and life expectancy. The clinical features, investigations and management of Duchenne muscular dystrophy are reviewed, as well as the latest in some of the novel therapies.
© 2015 The Authors. Journal of Paediatrics and Child Health © 2015 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Keywords:  Duchenne; corticosteroid; gene therapy; muscular dystrophy; non-invasive ventilation; positive pressure

Mesh:

Year:  2015        PMID: 25752877     DOI: 10.1111/jpc.12868

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  69 in total

1.  Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Tatiana M Fontelonga; Brennan Jordan; Andreia M Nunes; Pamela Barraza-Flores; Nicholas Bolden; Ryan D Wuebbles; Lesley Mathews Griner; Xin Hu; Marc Ferrer; Juan Marugan; Noel Southall; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

Review 2.  Gene Therapy for Heart Failure: New Perspectives.

Authors:  Khatia Gabisonia; Fabio A Recchia
Journal:  Curr Heart Fail Rep       Date:  2018-12

3.  Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice.

Authors:  Xuan Su; Yan Shen; Yue Jin; Meng Jiang; Neal Weintraub; Yaoliang Tang
Journal:  J Vis Exp       Date:  2019-04-10       Impact factor: 1.355

4.  Eosinophils Do Not Drive Acute Muscle Pathology in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Albert C Sek; Ian N Moore; Margery G Smelkinson; Katherine Pak; Mahnaz Minai; Roberta Smith; Michelle Ma; Caroline M Percopo; Helene F Rosenberg
Journal:  J Immunol       Date:  2019-05-29       Impact factor: 5.422

Review 5.  Skeletal muscle atrophy: disease-induced mechanisms may mask disuse atrophy.

Authors:  C J Malavaki; G K Sakkas; G I Mitrou; A Kalyva; I Stefanidis; K H Myburgh; C Karatzaferi
Journal:  J Muscle Res Cell Motil       Date:  2016-01-04       Impact factor: 2.698

Review 6.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

Review 7.  Determinants of the incidence of Duchenne muscular dystrophy.

Authors:  Alan Edmund Stark
Journal:  Ann Transl Med       Date:  2015-11

8.  Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.

Authors:  Xiaonan Li; Laurie S Conklin; John van den Anker; Eric P Hoffman; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2020-05-20       Impact factor: 3.126

9.  Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.

Authors:  Rika Maruyama; Toshifumi Yokota
Journal:  Methods Mol Biol       Date:  2021

10.  Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.

Authors:  Xu Liu; Yashuo Wang; Jennifer S Gutierrez; Jesse M Damsker; Kanneboyina Nagaraju; Eric P Hoffman; Eric A Ortlund
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.